Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel
about
New developments in the treatment of rosacea - role of once-daily ivermectin creamRosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory ConditionSkin barrier in rosaceaMajor pathophysiological correlations of rosacea: a complete clinical appraisalRecent advances in the understanding and management of rosacea.Management of cutaneous rosacea: emphasis on new medical therapies.Dermasence refining gel modulates pathogenetic factors of rosacea in vitro.Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefitReduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitorAzelaic Acid Topical Formulations: Differentiation of 15% Gel and 15% FoamEndoplasmic reticulum stress: key promoter of rosacea pathogenesis.Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Therapeutic targeting of Toll-like receptors in cutaneous disorders.Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics.Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.Severe Granulomatous Rosacea in a Boy Successfully Treated with Topical Azelaic Acid.Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel.Rosacea, the face of innate immunity.Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea.Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.
P2860
Q26751296-C843BF2F-0220-4C15-8E22-13079197D861Q28067747-15E26488-F911-43ED-9904-907ACA6ED859Q28069342-716C847C-4477-414B-BBF0-E82FE05A9C48Q28082171-1539EAAF-29A8-4ECD-AE56-D48F51E9FC76Q33942083-9E6422C8-2A73-476A-A695-226A846E21EEQ34436744-C3B0A7B2-8020-4132-A238-6358EAAACC0CQ36325038-5654CAC2-EE81-460C-B0F9-461E58386E3CQ37595472-87797A0A-6FB2-4352-AF7A-7D6E7D65FB83Q37676098-7A151720-10D7-4E75-B68C-13C31B663619Q37723073-CD753159-4F57-498E-AF6A-ECAF3291D234Q38232251-591972F5-67E9-4FF0-ADA8-56432688388EQ38236823-5A849C67-56AF-4C66-A21B-0871E8297E66Q38362486-B0EF73F4-3EFE-4153-90DD-49D69BC44428Q38550117-CA25287B-48BE-45D0-90F9-11318D8EF975Q38885566-416854F5-0F00-4C8F-8D5D-5CED9CF266CBQ42230578-09B093A8-3D00-4EA2-A06B-EBBDA1805726Q42596271-1B19D874-7F48-4835-8248-8364C3A47B56Q45153684-FC89566F-9D90-43C9-A26D-C7D86C934022Q46464886-A941EBEA-F5BD-4A30-A2DC-001706FE0637Q50559237-BD054633-7A4A-4D8C-8C1E-E67546CF83E5Q55340442-CA5315B7-D369-4E65-AECC-7BDFADD43B7D
P2860
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cathelicidin, kallikrein 5, an ...... acea with azelaic acid 15% gel
@en
Cathelicidin, kallikrein 5, an ...... cea with azelaic acid 15% gel.
@nl
type
label
Cathelicidin, kallikrein 5, an ...... acea with azelaic acid 15% gel
@en
Cathelicidin, kallikrein 5, an ...... cea with azelaic acid 15% gel.
@nl
prefLabel
Cathelicidin, kallikrein 5, an ...... acea with azelaic acid 15% gel
@en
Cathelicidin, kallikrein 5, an ...... cea with azelaic acid 15% gel.
@nl
P2093
P2860
P1476
Cathelicidin, kallikrein 5, an ...... acea with azelaic acid 15% gel
@en
P2093
Alvin B Coda
David Audish
Faiza Shafiq
James Q Del Rosso
Jeremiah Miller
Julie C Harper
Paul Kotol
Tissa Hata
P2860
P304
P356
10.1016/J.JAAD.2013.05.019
P407
P577
2013-07-18T00:00:00Z